Aphria (TSX:APHA) Soars 35%: Should You Buy This Marijuana Stock Today?

Aphria Inc. (TSX:APHA)(NYSE:APHA) just surprised the market. Is this the time to buy the stock?

edit Jars of marijuana

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Cannabis investors finally received some good news after weeks of downward pressure sent many of Canada’s top marijuana stocks towards 2019 lows.

What happened?

Aphria (TSX:APHA)(NYSE:APHA) became the first major pot producer to report a quarterly profit. The results surprise analysts and attracted a flood of money into the stock, sending the beleaguered marijuana company from $6.90 to above $9.40 per share. Short covering likely provided additional support.

Aphria delivered a revenue gain of 85% compared to the previous quarter. The company sold 5,574 kg of cannabis for revenue of $28.6 million compared to 2,636 kg for revenue of $15.4 million in the previous three months.

Production at the company’s 700,000-square-foot Aphria One site is at full capacity, and the company is moving through the process of getting its adjacent 1.2 million square foot Aphria Diamond facility licensed by Health Canada. Once the additional capacity is online, revenue and profits should continue to improve.

One point to note is that $50 million received from an American company, Green Growth Brands, as part of a settlement in the wake of a failed takeover bid was added in the quarter and contributed to the earnings report. Aphria says an additional $39 million is anticipated in October.

Back on track

Aphria took a big hit late last year when it became the target of a short-seller report that claimed Aphria had overpaid for assets it purchased in Latin America, benefitting people connected to the company.

Aphria’s senior management team initially said the claims were without merit. However, the company founders and the CEO left the firm in January. An investigation by the Ontario Securities Commission led to Aphria being forced to take a $50 million impairment charge on the assets in question.

The stock traded above $21 per share last September and bottomed out around $5 after the short-seller report came out last December. A rebound took it back to $14 in February, but Aphria had drifted consistently lower until the August 2nd bounce.

Should you buy Aphria?

The improvement in sales is a positive sign, and it appears the new management team the board brought in to rebuild the company’s credibility is making good progress. With the new production facility expected to get licensed in the near term, sales and revenue growth should continue into 2020.

I would probably wait for a few days to see if Aphria gives back some of the big gains, but contrarian investors who are positive on the sector might want to start nibbling on the stock once the euphoria settles.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Andrew Walker has no position in any stock mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »